⁇ -sinüklein ve tau genotipleri arasındaki etkileşim ve Parkinson hastalığının ilerlemesi.
Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease.
DOI: 10.3233/jpd-2011-11027PMID: 23939307
“Parkinson progression” Aramayı temizle
Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease.
DOI: 10.3233/jpd-2011-11027PMID: 23939307
Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times.
DOI: 10.1016/j.parkreldis.2010.11.010PMID: 21159539
The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: a review.
DOI: 10.3109/00207454.2010.535934PMID: 21126109
Charting the progression of disability in Parkinson disease: study protocol for a prospective longitudinal cohort study.
DOI: 10.1186/1471-2377-10-110PMID: 21047426
Lack of motor symptoms progression in Parkinson's disease patients with long-term bilateral subthalamic deep brain stimulation.
DOI: 10.3109/00207454.2010.518777PMID: 20942586
Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease.
DOI: 10.1111/j.1460-9568.2010.07448.xPMID: 20964730
Instability of syllable repetition as a marker of disease progression in Parkinson's disease: a longitudinal study.
DOI: 10.1002/mds.23382PMID: 20945431
Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects.
DOI: 10.1016/j.neuroimage.2010.09.028PMID: 20851193
[Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria].
DOI: 10.1016/j.neurol.2010.07.005PMID: 20800250
Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.
DOI: 10.2967/jnumed.110.076802PMID: 20660377
Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression.
DOI: 10.1016/j.nbd.2010.07.004PMID: 20655384
Clinical progression in Parkinson disease and the neurobiology of axons.
DOI: 10.1002/ana.21995PMID: 20517933
Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.